Which listed company manufacturer is Larotinib/Larotinib?

Larotrectinib/Larotrectinib was originally developed by the American company Loxo Oncology, which focuses on the development of targeted cancer treatment drugs. In 2019, Loxo Oncology was acquired by Eli Lilly and Company. Subsequently, Bayer obtained the global commercialization rights of larotrectinib and was responsible for the production and sales of the drug. Currently, larotrectinib has been approved for marketing in many countries and regions, including the United States, the European Union and China, and is used to treat patients with solid tumors carrying NTRK gene fusion mutations. As a breakthrough broad-spectrum anti-cancer drug, Bayer leads the commercialization layout of larotrectinib and continues to promote its global indication expansion and market promotion to benefit more patients.